David Lacey
Chairman at NURIX THERAPEUTICS, INC.
Net worth: 1 M $ as of 2024-03-30
David Lacey active positions
| Companies | Position | Start | End |
|---|---|---|---|
| NURIX THERAPEUTICS, INC. | Independent Dir/Board Member | 2016-03-31 | - |
| Chairman | 2019-07-31 | - | |
| Director/Board Member | 2016-03-31 | 2019-07-31 | |
| ATRECA, INC. | Director/Board Member | 2016-05-30 | - |
| Independent Dir/Board Member | 2016-05-30 | - | |
| ARCUS BIOSCIENCES, INC. | Director/Board Member | 2020-05-20 | - |
| Independent Dir/Board Member | 2020-05-20 | - | |
Inbiomotion SL
 Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Director/Board Member | 2012-11-30 | - |
| Independent Dir/Board Member | 2012-11-30 | - | |
Ysios Capital Partners SGEIC SA
 Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Private Equity Investor | 2020-05-31 | - |
Career history of David Lacey
Former positions of David Lacey
| Companies | Position | Start | End |
|---|---|---|---|
| ARGENX SE | Director/Board Member | 2014-07-08 | 2021-05-10 |
| Independent Dir/Board Member | 2014-07-08 | 2021-05-10 | |
| UNITY BIOTECHNOLOGY, INC. | Director/Board Member | 2018-02-06 | 2020-12-13 |
| Independent Dir/Board Member | 2018-02-06 | 2020-12-13 | |
| AMGEN INC. | Corporate Officer/Principal | 1993-12-31 | 2010-12-31 |
| The University of Colorado | Corporate Officer/Principal | - | - |
| ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Training of David Lacey
| The University of Colorado | Undergraduate Degree |
| The University of Colorado School of Medicine | Doctorate Degree |
Statistics
International
| United States | 10 |
| Spain | 3 |
| Netherlands | 2 |
Operational
| Director/Board Member | 7 |
| Independent Dir/Board Member | 6 |
| Corporate Officer/Principal | 3 |
Sectoral
| Health Technology | 9 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 6 |
|---|---|
| AMGEN INC. | Health Technology |
| ATRECA, INC. | Health Technology |
| NURIX THERAPEUTICS, INC. | Health Technology |
| ARGENX SE | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Finance |
Jewish Hospital
 Jewish Hospital Hospital/Nursing ManagementHealth Services Part of Community Health Systems, Inc., Jewish Hospital is a hospital. The private company is based in Cincinnati, OH. Jewish Hospital was acquired by Mercy Health Partners, Inc. (Pennsylvania), a NPO of Community Health Systems, Inc. from Jewish Foundation of Cincinnati on March 01, 2010 for $180 million. | Health Services |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Health Technology |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
- Stock Market
- Insiders
- David Lacey
- Experience
